# Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

> **NCT03072043** · PHASE1,PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 55 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Acute Myeloid Leukemia
- Myeloproliferative Neoplasm
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** APR-246
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT03072043
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-18
- **Primary completion:** 2019-11-15
- **Final completion:** 2021-12-08
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2022-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03072043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03072043, "Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03072043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*